摘要
目的:分析重组人白细胞介素2(rhIL-2)联合冷冻疗法对子宫颈炎合并HPV感染患者免疫功能、氧化应激的影响。方法:选取2020年1-12月泰和县中医院收治的97例子宫颈炎合并HPV感染患者,使用随机数字表法将其分为对照组(n=48)和观察组(n=49)。对照组给予单纯冷冻疗法治疗,观察组给予rhIL-2联合冷冻疗法治疗。比较两组临床体征评分、HPV-DNA载量、免疫球蛋白(IgA、IgG、IgM)、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)]水平及疗效。结果:治疗后,观察组阴道分泌物异常、子宫颈炎症深度、子宫颈炎症面积评分、HPV-DNA载量、MDA水平均低于对照组,HPV转阴率及IgA、IgG、IgM、SOD水平均高于对照组(P<0.05)。观察组总有效率为93.88%,高于对照组的77.08%,差异有统计学意义(P<0.05)。结论:rhIL-2联合冷冻疗法可有效调节子宫颈炎合并HPV感染患者免疫能力水平,减轻氧化应激反应,抑制炎症反应,优化临床疗效。
Objective:To analyze the effects of recombinant human interleukin-2(rhIL-2)combined with cryotherapy on immune function and oxidative stress in patients with cervicitis complicated with HPV infection.Method:A total of 97 patients with cervicitis complicated with HPV infection admitted to Taihe Hospital of Traditional Chinese Medicine from January to December 2020 were selected,they were divided into control group(n=48)and observation group(n=49)according to random number table method.The control group was treated with cryotherapy alone,while the observation group was treated with rhIL-2 combined with cryotherapy.The clinical sign scores,HPV-DNA load,immunoglobulin(IgA,IgG,IgM),oxidative stress index[superoxide dismutase(SOD),malondialdehyde(MDA)]and efficacy were compared between the two groups.Result:After treatment,the vaginal discharge was abnormal,cervical inflammation depth,cervical inflammation area score,HPV-DNA load and MDA level were lower than the control group,and the HPV negative turn rate and IgA,IgG,IgM and SOD levels were higher than the control group(P<0.05).The total response rate of the observation group was 93.88%,which was higher than the 77.08%of the control group,and the difference was statistically significant(P<0.05).Conclusion:rhIL-2 combined with cryotherapy can effectively regulate the level of immune ability in patients with cervicitis complicated with HPV infection,reduce oxidative stress response,inhibit inflammatory response and optimize clinical efficacy.
作者
张裕龙
张裕斌
姜俊敏
ZHANG Yulong;ZHANG Yubin;JIANG Junmin(Taihe Hospital of Traditional Chinese Medicine,Jiangxi Province,Taihe 343700,China;不详)
出处
《中国医学创新》
CAS
2022年第25期72-77,共6页
Medical Innovation of China